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Introduction
Rituximab is a monoclonal antibody which enhances
the treatment efficacy of B-lineage lymphomas.1,2 It
may be associated with compromise of immunity and
subsequent opportunistic infections.3,4 Pneumocystis
jiroveci (previously known as P. carinii) pneumonia
(PCP) may occur in a wide range of hematologic dis-
eases, notably lymphomas.5–7 In lymphomas, its inci-
dence appears to be related to treatment intensity.8 With
the standard regimen of cyclophosphamide, doxoru-
bicin, vincristine and prednisolone (CHOP) with or
without rituximab, such an opportunistic infection
occurs infrequently. However, PCP can be possibly
overlooked, so the true incidence is obscure. The pres-
ent published guidelines for empirical therapy for febrile
neutropenic patients do not include PCP in the early
assessment,9,10 which may potentially cause delay in its
diagnosis. In this report, we present 2 cases with PCP
that occurred after chemotherapy containing rituximab,
and discuss the importance of clinical alertness in the
neutropenic period.
Case Reports
Case 1
A 45-year-old female was diagnosed with follicular
lymphoma, grade I, in December 2005. The tumor
was in stage IVA, with bone marrow involvement. She
received chemotherapy with CHOP, consisting of:
cyclophosphamide 750 mg/m2, day 1; doxorubicin
50 mg/m2, day 1; vincristine 2 mg, day 1; and pred-
nisolone 100mg/day for 5 days. The same regimen was
repeated in 3 weeks. Severe neutropenia (white blood
cell count [WBC] 1,900/mm3 and absolute neutrophil
count 437/mm3) and digital paresthesia occurred
following chemotherapy, although there was no overt
infection. Doxorubicin was omitted in the 3rd cycle of
chemotherapy. Rituximab 375 mg/m2 was added to
the treatment (R-CHOP). Only 75% of doxorubicin
was given in the 4th, 5th and 6th cycles.
On April 19, 2006, after 3 cycles of R-CHOP and
a total of 6 cycles of chemotherapy, the patient was
admitted with fever. She also complained of cough with
scant sputum and mild substernal chest pain. Physical
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examination did not show remarkable findings. Labo-
ratory data showed hemoglobin of 12.8g/dL, platelets
of 208,000/mm3, and WBC of 1,300/mm3 with 83%
neutrophils, 5% monocytes, 2% eosinophils, 9% lympho-
cytes and 1% basophils. Biochemistry profile showed
normal liver and renal functions. Initial chest film
showed only slightly exaggerated lung markings. The
patient was treated with ciprofloxacin 300 mg intra-
venous infusion every 12 hours. The fever persisted,
and chest X-ray taken 3 days later revealed some ground
glass appearance in the left lung and right lower lung
fields (Figure 1A). A high-resolution computed tomog-
raphy (HRCT) scan the next day disclosed patchy
consolidation of bilateral perihilar areas (Figure 1B).
The patient did not receive bronchoscopy, and no
sputum was available for microbiologic examination.
As PCP was suspected, treatment with trimethoprim-
sulfamethoxazole (TMP-SMX) was given at a dose of
TMP 5 mg/kg every 6 hours. Fever subsided 2 days
after starting TMP-SMX. The treatment was contin-
ued for 21 days. Adjunctive steroid was used for 10
days and then tapered off. Follow-up chest film showed
a normal result, and the patient was discharged after
completing the treatment course for PCP. Another 2
cycles of rituximab plus chemotherapy were given.
The dose of doxorubicin was further reduced to 66%
in the 7th cycle and omitted in the 8th cycle. No pro-
phylaxis for PCP was given, and she had no further
complications.
Case 2
A 45-year-old housewife was diagnosed with extra-
nodal marginal zone B-cell lymphoma with diffuse large
cell transformation in March 2006. The tumor was 
in stage IIEA, with involvement of the stomach and
regional lymph nodes. The patient was a hepatitis B
carrier, and lamivudine was given as prophylaxis for
hepatitis B flare up. She received chemotherapy with
CHOP. Neutropenic fever occurred following the first
cycle of chemotherapy. Further chemotherapy was
given every 3 weeks with dose reduction. Rituximab
375mg/m2 was added to the treatment (R-CHOP)
starting from the 3rd cycle of chemotherapy. Due to
recurrent severe neutropenia after each cycle of treat-
ment, doxorubicin was omitted in the 6th cycle of
chemotherapy on June 26, 2006.
Neutropenic fever developed on July 11 (WBC
2,000/mm3) and she also had mild dry cough. Physical
examination showed mild tachypnea (respiratory rate
of 28/min) but otherwise unremarkable findings. The
initial chest film showed slightly exaggerated lung mar-
kings. The patient was treated with ceftriaxone 1g intra-
venous injection every 12 hours for 3 days. As the fever
persisted, treatment was changed to flomoxef. Chest
film was followed-up 6 days later, revealing ground
glass appearance in the left lung field (Figure 2A).
HRCT scan on the same day revealed slight thicken-
ing of the interlobular septa and intralobular intersti-
tium in the left lung with multifocal ground glass
opacities (Figure 2B).
Gomori’s methenamine silver nitrate stain of the
bronchoalveolar fluid detected the existence of P. jiroveci
in the lungs. Treatment with TMP-SMX at a dose of
TMP 5 mg/kg every 6 hours was instituted, and the
fever subsided the following day. Seven days after
starting TMP-SMX, WBC decreased to 1,900/mm3
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Figure 1. (A) Chest X-ray of Case 1 shows some ground glass appearance in the left lung and right lower lung fields. (B) High-resolution
computed tomography shows patchy consolidation of bilateral perihilar areas.
with 1% myelocytes, 82% neutrophils, 8% monocytes,
1% eosinophils and 8% lymphocytes. Follow-up chest
film showed no more infiltrates. TMP-SMX was re-
placed with clindamycin 600 mg intravenous infusion
every 8 hours for suspected TMP-SMX-related neu-
tropenia. The treatment was continued for a total of
21 days. No prophylaxis for PCP was given following
complete treatment. Two more cycles of R-CHOP
were given without further complications.
Discussion
PCP is an opportunistic infection occurring in immu-
nocompromised hosts such as those with acquired
immunodeficiency syndrome (AIDS) or recipients of
organ transplantations. PCP may occur in a variety of
hematologic diseases, including non-Hodgkin’s lym-
phoma, chronic lymphocytic leukemia, acute leukemias,
chronic myeloid leukemia, multiple myeloma, myelo-
dysplastic syndrome, Hodgkin’s disease and thromobo-
cytopenia.5–7 Stem cell transplantation is by far the most
immunocompromised state among hematologic dis-
eases.11 Such patients usually receive TMP-SMX pro-
phylaxis. The incidence of PCP in such a prophylactic
setting is low.11 For patients treated with conventional
chemotherapy, non-Hodgkin’s lymphoma is the most
common malignancy associated with such opportunis-
tic infections.5–7 It has been well demonstrated that
chemotherapy used for lymphoma may cause severe
and prolonged depression of CD4 cell counts and levels
of immunoglobulin G.12 In some intensive treatment
modalities, PCP occurs so frequently that routine
prophylaxis is recommended.8,13
Compared with infection caused by other patho-
gens, PCP can be significantly overlooked, especially
in the presence of neutropenia. The treatment guide-
lines for empirical therapy of febrile neutropenia dose
not include treatment for PCP in the early phase.9,10
As PCP patients frequently have hypoxemia, failure to
recognize early PCP may result in unfavorable out-
comes. Both of our cases developed PCP in the setting
of febrile neutropenia. Both received broad-spectrum
antibiotics as the initial empirical treatment. With clin-
ical alertness, the diagnosis of PCP was suspected by
chest films taken 3 and 6 days after the onset of fever.
In both cases, diagnosis was supported by HRCT on
the same day that the chest film was taken. Specific
treatment of PCP was also initiated on the same day.
Bronchoalveolar lavage cytology was performed in
Case 2, confirming the diagnosis by Gomori’s methe-
namine silver nitrate stain. Our experience demon-
strated that PCP should be listed in the differential
diagnoses of febrile neutropenia in patients with hema-
tologic diseases, especially lymphoma. Early evaluation
for PCP should also be considered in the treatment
guidelines for such patients. As for treatment, although
TMP-SMX is effective in the majority of cases, it may
be intolerable due to gastrointestinal upset, allergic reac-
tions or bone marrow suppression. In such conditions,
clindamycin/primaquine is an alternative therapy,14,15
as illustrated by the use of clindamycin in Case 2 (pri-
maquine was not available in our ward at that time).
Rituximab is a chimeric monoclonal antibody di-
rected against CD20. Used in conjunction with con-
ventional chemotherapy, it increases the treatment
efficacy of B-lineage lymphomas.1,2 On the other hand,
it may cause immunosuppression, rendering patients
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Figure 2. (A) Chest X-ray of Case 2 shows ground glass appearance in the left lung field. (B) High-resolution computed tomography
reveals slight thickening of the interlobular septa and intralobular interstitium in the left lung with multifocal ground glass opacities.
prone to infection by microorganisms such as fungi
and cytomegalovirus.3,4
In the clinical trials done by Coiffier et al, 197
patients aged between 60 and 80 years received treat-
ment with CHOP, while 202 patients received R-
CHOP. In the R-CHOP arm, there were 12 cases with
grade 3 to 4 infection and 8 cases of lung toxicity, but
no case with frank PCP was reported.1 Another con-
trolled randomized trial enrolled 824 patients between
18 and 60 years of age. No case with frank PCP was
reported in either arm.1 Whether or not PCP prophy-
laxis was given to the enrolled cases was not described,
but it can be shown that PCP is rare during such treat-
ment courses. On the other hand, in more intensive
treatment, patients were given R-CHOP at a 2-week
interval; 7 interstitial pneumonitis and 3 documented
PCP cases occurred among 50 patients.8 It was also
demonstrated that occurrence of PCP was correlated
with hypogammaglobulinemia.8 It reflected that immu-
nosuppression may be more profound during more
intensive treatment and the likelihood for developing
opportunistic infection higher. Since rituximab sup-
presses CD20+ lymphocytes and leads to hypogam-
maglobulinemia, it will add to the potential risk of PCP
or other opportunistic infections.
In clinical practice, PCP can be easily overlooked
in patients treated with conventional regimens. In the
absence of routine prophylaxis with TMP-SMX, the
true incidence is not shown in any large-scale studies.
Our cases received chemotherapy containing rituximab
at the conventional 3- to 4-week intervals. PCP was
not reported in previous clinical trials that used treat-
ment of similar intensity. It is hoped that this report
will draw attention to this opportunistic infection. As
early diagnosis and proper treatment are important,
clinicians should be highly alert to such complications.
Although the guidelines for febrile neutropenia do not
include PCP in the early assessment, PCP should be
considered in the early phase of febrile neutropenia in
patients with hematologic malignancies. Prophylaxis
with TMP-SMX may be warranted if more studies
showing the occurrence of PCP are available in the
future.
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